Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568560 | 0.78 | — | — | |
| SCHEMBL25568561 | 0.78 | — | — | |
| SCHEMBL7875657 | 0.78 | — | — | |
| SCHEMBL18648164 | 0.76 | PRMT1 (0.35) | CARM1PRMT1PRMT3PRMT6PRMT8 | |
| SCHEMBL15564200 | 0.75 | CARM1 (0.31) | CARM1PRMT1 | |
| SCHEMBL26510209 | 0.73 | ACHE (0.36) | CARM1PRMT1PRMT6PRMT8 | |
| SCHEMBL25300386 | 0.73 | CYP1A2 (0.52) | — | |
| SCHEMBL18648162 | 0.73 | CYP1A2 (0.52) | — | |
| SCHEMBL18648166 | 0.73 | CYP1A2 (0.52) | — | |
| SCHEMBL1245675 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277406-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2020-09-03 | — | — | US | disclosed |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633460-B2 | Binding agent | ROCHE DIAGNOSTIC OPERATIONS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-2036897-B1 | Stable rhodamine labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289251-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289251-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012085111-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085113-A1 | BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085064-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085069-A2 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2036897-A1 | Stable rhodamine labeling reagent | Roche Diagnostics GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289251-A1 | BINDING AGENT | SSB, APBA1, SHBG | CARM1 4242/4885PRMT1 2976/4885PRMT3 3774/4885 |
| US-20170275381-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BIVALENT BINDING AGENT | PTMS, CD2BP2, PSMA2 | CARM1 3669/4885PRMT1 2093/4885PRMT3 2091/4885 |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 11/4885PRMT1 1/4885PRMT3 2/4885 |
| US-20130288266-A1 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT | PTMS, DNPEP, CD2BP2 | CARM1 4071/4885PRMT1 1572/4885PRMT3 1491/4885 |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | CARM1 4071/4885PRMT1 3165/4885PRMT3 2520/4885 |
| US-10633460-B2 | Binding agent | SSB, APBA1, SHBG | CARM1 4220/4885PRMT1 2979/4885PRMT3 3780/4885 |
| US-20130288267-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | CARM1 3273/4885PRMT1 2688/4885PRMT3 2769/4885 |
| US-20170275380-A1 | DETECTION OF A POLYPEPTIDE DIMER BY A BIVALENT BINDING AGENT | PA2G4, BRDT, CD2BP2 | CARM1 3273/4885PRMT1 2688/4885PRMT3 2769/4885 |
| US-20200277406-A1 | BINDING AGENT | SSB, APBA1, SHBG | CARM1 4220/4885PRMT1 2979/4885PRMT3 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.